The Spanish company, Biontaxis, a spin-off of the Institut d’Investigació Germans Trias i Pujol de Badalona (Barcelona) specializing in neurological diseases, has obtained public funding from the Government for a value of €1.1 million.
Biontaxis has obtained funding through the European Recovery and Resilience Mechanism through the Center for Industrial Technological Development (Cdti) for its gene therapy project for Friedrich’s ataxia.
Friedreich’s ataxia is a neurodegenerative disease that is considered a rare disease. Mainly, it affects the ability to develop movements, such as walking and talking. The disease progressively aggravates incapacity and lack of autonomy. There is no cure, in case the cause is known, a defect in a gene that produces a mitochondrial protein called frataxin. The genetic problem produces a deficiency of this protein, which damages the neurons of the spinal cord and the cerebellum.
Read more about Biontaxis and find the most important business news of the day with the Born2Invest mobile app.
Biontaxis wants to develop and validate a gene therapy vector based on a new generation of adeno-associated virus
The company will use the resources to continue financing the development of a drug against Friedrich’s ataxia. The research is led by Antoni Matilla and Ivelisse Sánchez from the neurogenetics research group of the Germans Trias i Pujol Research Institute with the collaboration of neurologists from the neurology department of the Germans Trias Hospital and the Valdecilla de Santander Hospital.
The purpose of the project is to develop and validate a gene therapy vector based on a new generation of adeno-associated virus to be effective as a curative treatment in patients with Friedreich’s ataxia. The program is intended to finance experimental development projects in advanced therapies and personalized medicine in cooperation between companies and research organizations.
The next step for the company is to preclinically validate the drug in large animals to complete the preclinical validation as a phase prior to applying to the regulatory agencies for the corresponding authorization to bring the therapy to the clinical stage.
Friedrich’s ataxia is a rare disease that affects one in 40,000 people
Biointaxis was created in 2018 at the Germans Trias i Pujol Research Institute. Throughout its history, the company has received more than two million euros from the Center for Industrial Technological Development (Cdti), a public business entity whose objective is to promote innovation and technological development in Spanish companies, and from Caixa Capital Risc, CriteriaCaixa’s venture capital manager that invests in innovative companies in their initial and growth stages.
Friedrich’s ataxia is a rare disease that affects one in 40,000 people in the world and that appears between the ages of five and twenty, causing degeneration that ends up sending patients to a wheelchair, among many other problems. of health.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [uMobix Affiliate Program Review]
This week, we're covering everything from hustle culture to spying on kids, making this affiliate digest look like it has...
Stanford University Returns Millions from FTX
Between November 2021 and May 2022, Bankman directed donations of more than €5.5 million from FTX Group to Stanford University....
Biova Project Launched an Equity Crowdfunding Campaign on Mamacrowd
Biova Project makes deals with players in large-scale distribution and production to recover, store, and transform unsold food, or food...
Novo Nordisk Plans to Open a Tech Headquarters in Spain
Novo Nordisk increased its profit by 42.5% in the first half of 2023, reaching 39,242 million Danish crowns (€5.26 million)....
Immorente Invest Maintains its Financial Stability
Although the occupancy rate has fallen from 92% to 90.2% compared with the end of 2022, the company expects this...
Business2 weeks ago
Argentinian Grilling Had One Big Problem… Then Kankay Came Along
Business3 days ago
Use This AI-Powered Money Saving App to Boost Your Finances
Crowdfunding1 week ago
Real Estate Crowdfunding Has Raised Over €45 Billion Worldwide
Crowdfunding6 days ago
Out Of Raises €2.4 Million Through Equity Crowdfunding, in 2 Weeks